Document Detail


Current status of taxanes as adjuvant therapy for early-stage breast cancer.
MedLine Citation:
PMID:  16468473     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Several factors explain the significant improvement in outcome among patients diagnosed with breast cancer over the last 20 years. Chief among them are the greater adoption of screening strategies and an improved understanding of the benefit offered by adjuvant systemic therapy in reducing the risk of cancer recurrence and death. Predictive markers of response like the estrogen receptor (ER) and the human epidermal growth factor receptor 2 (HER2) help identify those most likely to derive a survival benefit from adjuvant therapy with anti-estrogens and trastuzumab therapy, respectively. However, despite the lack of robust predictive markers of clinical benefit, adjuvant systemic chemotherapy is an effective tool to improve the survival odds of breast cancer patients, especially those with ER-negative breast cancer. The Oxford Overview confirmed the incremental benefit offered by the use of anthracycline-containing regimens in the adjuvant setting. After being approved in the early 1990's for the treatment of advanced breast cancer, the taxanes gradually established themselves as useful drugs in the adjuvant setting. In this commentary, we review much of the current data that support the use of taxanes in early-stage breast cancer.
Authors:
Antonio C Wolff
Related Documents :
12234503 - A randomised comparison of bicalutamide ('casodex') 150 mg versus placebo as immediate ...
11249513 - Colorectal cancer staging and adjuvant chemotherapy.
3609913 - Laboratory monitoring of a low molecular weight heparin (enoxaparin) with a new clottin...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  International journal of fertility and women's medicine     Volume:  50     ISSN:  1534-892X     ISO Abbreviation:  Int J Fertil Womens Med     Publication Date:    2005 Sep-Oct
Date Detail:
Created Date:  2006-02-10     Completed Date:  2006-04-04     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  9706778     Medline TA:  Int J Fertil Womens Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  227-9     Citation Subset:  IM    
Affiliation:
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland 21231-1000, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents, Phytogenic / therapeutic use*
Breast Neoplasms / drug therapy*,  pathology
Chemotherapy, Adjuvant
Female
Humans
Neoadjuvant Therapy
Paclitaxel / therapeutic use
Taxoids / therapeutic use*
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Phytogenic; 0/Taxoids; 15H5577CQD/docetaxel; 33069-62-4/Paclitaxel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  New approaches in breast cancer management: sentinel node biopsy and intraoperative radiotherapy.
Next Document:  Exercise for breast cancer survival: the effect on cancer risk and cancer-related fatigue (CRF).